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(age 18+). The current analysis was limited to respondents from
the UK. Individuals who reported having private health insur-
ance were 1:1 matched with those who did not on age, gender
and highest education level attained (college graduate vs. no
college). Paired t-tests were conducted to assess if any differences
existed for continuous variables. For dichotomous variables,
odds ratios were calculated to determine the likelihood of an
individual with health insurance experiencing comorbidities
compared to those without health insurance, and signiﬁcant dif-
ferences were tested using McNemar’s chi-square. RESULTS: Of
the 1944 respondents with private health insurance, 1925 were
matched to controls without health insurance yielding a 99%
match. Cases were generally healthier than controls. Cases had
higher SF-8 physical summary scores (49.73 vs 47.79, p < 0.001)
and SF-8 mental summary scores (49.72 vs 48.39, p < 0.001)
than controls. Cases had a signiﬁcantly decreased likelihood of
experiencing angina, COPD, heart attacks, over-active bladder,
abdominal bloating, anxiety, emphysema, depression, general-
ized anxiety disorder, pain, panic disorder and social anxiety
disorder. Cases experienced less activity impairment than con-
trols as measured by the Work Productivity and Activity Impair-
ment (WPAI) Questionnaire (19.18% vs. 25.12%, p < 0.001).
However, no signiﬁcant differences were noted for resource
utilization between those with and without private health insur-
ance. CONCLUSION: Unique characteristics differentiate those
with and without private health insurance in the UK. These
differences have ramiﬁcations for health policy and health care
spending.
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OBJECTIVES: To demonstrate that in European pricing and
reimbursement the beneﬁts of the pharmaceutical industries can
be optimised. METHODS: We have examined the reimburse-
ment criteria and drug price establishments of 12 European
countries: UK, The Netherlands, Germany, Sweden, Norway,
Belgium, Italy, Spain, France, Austria, Denmark and Switzerland.
Reimbursement systems were compared across six key reim-
bursement criteria (clinical efﬁcacy, cost effectiveness, budget
impact, foreign price reference, public medical need, value of
treatment) and classiﬁed into three categories whether a Cost
Effectiveness Analysis (CEA) is mandatory, optional or absent. In
parallel, two types of pricing system were identiﬁed: no pricing
reference and reference pricing. We have developed a network
model to demonstrate the relative monetary beneﬁts resulting
from the pricing and reimbursement systems behaviour.
RESULTS: We found that majority of countries determine drug
price before the reimbursement decision in order to perform a
CEA. However in other countries where CEA are optional or
absent, reimbursement decisions generally precede price negotia-
tions. The most important aspect of pricing for all countries
except Germany and UK is the price in other reference countries
(e.g. the price in France is the average of Spain, Italy, Germany
and UK drug prices). Therefore a higher price obtained in Spain
could increase the French drug price. Other countries (like
Belgium or Italy) set price according to speciﬁc country. Prag-
matically each country has its own ﬁxed budget allocated to
different diseases; therefore a reimbursement and price determi-
nation across Europe should be approached strategically to opti-
mise margins and beneﬁts. CONCLUSION: The applications of
CEA for decision making have progressed in European countries
constraining prices and costs to effectiveness. Nevertheless, in
other countries drug prices are more sensitive to public health
and are negotiated with public authorities. A European national
pricing and reimbursement approach by disease network model
could generate optimal monetary beneﬁt for the pharmaceutical
industry.
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OBJECTIVES: The purpose of the study was to compare and
contrast reference pricing with health technology assessment
(HTA) as alternative strategies for obtaining value for money
from pharmaceuticals. METHODS: The study focussed on
decisions about the initial price and reimbursement status of
innovative drugs. Four countries were studied: Germany, The
Netherlands, Sweden and the UK. These countries have operated
one, or both, of the two policies at certain points in time,
sometimes in parallel. Drugs in four groups were considered:
cholesterol-lowering agents, insulin analogues, biologics for
rheumatoid arthritis and atypicals for schizophrenia. RESULTS:
Where reference pricing schemes were in operation, all the drugs
obtained reimbursement. In addition, all the drugs in the same
group were placed in the same cluster. Prices were also similar,
with the exception of cholesterol-lowering agents, where some
generic agents were available. Where technology assessments had
been performed, the use of some drugs (e.g. insulin analogues)
was restricted more than the licensed indication. On occasions,
technology assessments were used to assess whether a premium
price was justiﬁed for a given product. CONCLUSION: Com-
pared with HTA, reference pricing is a relatively blunt instrument
for obtaining value for money from pharmaceuticals. It may have
a role alongside HTA, in making reimbursement decisions about
those drugs which, because of resource constraints, cannot be
subjected to a technology assessment.
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OBJECTIVES: The new Single Technology Appraisal (STA)
process introduced by NICE attempts to shorten the process of
assessment. The purpose of this study was to review, summarise
and critique all of the STAs published to date and to analyse
themes and trends. METHODS: A database was developed to
collate key data from the STAs completed to date with an initial
focus on oncology submissions. Clinical and economic data as
well as summaries of all key comments were extracted from the
manufacturer submission, evidence review group report, expert
submission and the ﬁnal appraisal determination. Data were then
analysed for associations between ICER values, clinical and eco-
nomic evidence and submission outcome. RESULTS: Since the
introduction of the STA process, six STAs have been completed
for drugs in oncology. A further 27 STAs are in development,
with 10 more in oncology. Three out of the six oncology sub-
missions were considered to have resulted in positive guidance
from NICE, recommending the use of the drug in the NHS.
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